Heart Disease Clinical Trials in Seattle

Showing 81-100 of 117 trials

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NCT01953874

The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and sleep.

Acute Decompensated Heart FailureSleep Disordered Breathing

ResMed126 participantsStarted Dec 2013

Huntsville, Alabama, United States • Los Angeles, California, United States • Denver, Colorado, United States +12 more locations

COMPLETEDPHASE3< 1 mile

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

NCT00048308

During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.

Cardio-pulmonary BypassCoronary Artery Bypass Graft

Alexion Pharmaceuticals, Inc.3,000 participantsStarted Jan 2002

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Mobile, Alabama, United States +183 more locations

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Heart Disease Trials in Other Cities

Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults

Niacin Plus Statin to Prevent Vascular Events

Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality

TAXUS PERSEUS Workhorse

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Naltrexone/Bupropion Cardiovascular Outcomes Study

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

Heart Outcomes Prevention and Evaluation 4

Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017

POC - Transfusion Algorithm Cardiac Study

Improvement of Patients With Chronic Heart Failure Using NT-proBNP

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.

TAXUS Libertē Post Approval Study

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

Other Conditions in Seattle